CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02580552
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:56.017342+00:00
Published At: 2020-11-23T00:00:00+00:00
Record Updated At: 2020-11-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cutaneous T-cell Lymphoma (CTCL)", "Mycosis Fungoides (MF)", "Chronic Lymphocytic Leukemia (CLL)", "Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype", "Adult T-Cell Leukemia/Lymphoma (ATLL)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-11-23"
protocolSection.identificationModule.nctId: "NCT02580552"
protocolSection.identificationModule.officialTitle: "A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.